Abstract
Androgen deprivation in patients with metastatic prostate cancer produces palliation of symptoms, reduction in PSA levels, and temporary regression of tumor in most patients. Following a brief period of disease regression that lasts an average of eighteen to twenty-four months, the disease becomes hormone refractory and progresses. Second line hormonal manipulation includes anti-androgen withdrawal, glucocorticoids, estrogens, aminogluthetimide, and ketoconazole. The response from these drugs is usually very short. Once these measures have been exhausted, the clinician is left with limited treatment options that include radionuclides and cytotoxic chemotherapy. It is the objective of this article to review the experience with chemotherapy in prostate cancer and then to discuss the role of radionuclide agents, emerging agents, and herbal therapies.
Keywords: Radioisotopes, bone metastases, taxanes, Mitoxantrone, prostate specific antigen (PSA), prednisone, Small cell carcinoma
Current Pharmaceutical Design
Title: Chemotherapy for Prostate Cancer
Volume: 12 Issue: 7
Author(s): Sara W. Dyrstad, Prabodh Shah and K. Rao
Affiliation:
Keywords: Radioisotopes, bone metastases, taxanes, Mitoxantrone, prostate specific antigen (PSA), prednisone, Small cell carcinoma
Abstract: Androgen deprivation in patients with metastatic prostate cancer produces palliation of symptoms, reduction in PSA levels, and temporary regression of tumor in most patients. Following a brief period of disease regression that lasts an average of eighteen to twenty-four months, the disease becomes hormone refractory and progresses. Second line hormonal manipulation includes anti-androgen withdrawal, glucocorticoids, estrogens, aminogluthetimide, and ketoconazole. The response from these drugs is usually very short. Once these measures have been exhausted, the clinician is left with limited treatment options that include radionuclides and cytotoxic chemotherapy. It is the objective of this article to review the experience with chemotherapy in prostate cancer and then to discuss the role of radionuclide agents, emerging agents, and herbal therapies.
Export Options
About this article
Cite this article as:
Dyrstad W. Sara, Shah Prabodh and Rao K., Chemotherapy for Prostate Cancer, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056100
DOI https://dx.doi.org/10.2174/138161206776056100 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)
Clinical Cancer Drugs Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective
Current Topics in Medicinal Chemistry Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Genome Projects and the Functional-Genomic Era
Combinatorial Chemistry & High Throughput Screening Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Intracellular Trafficking of MDR Transporters and Relevance of SNPs
Current Topics in Medicinal Chemistry Epigenetic Mechanisms Underlying Diet-Sourced Compounds in the Prevention and Treatment of Gastrointestinal Cancer
Anti-Cancer Agents in Medicinal Chemistry Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging